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Chemotherapy is one of the most common treatments 
for many kinds of cancer. The effectiveness of chemother-
apy is limited at least in part by dr�g resistance of cancer 
cells.  In recent years� there has been m�ch effort toward 
identifying agents that are able to sensitize cancer cells 
to conventional anti-cancer dr�gs [�� �]. The Teucrium 
polium L. is a wild growing flowering plant and is fo�nd in 
so�th western Asia and E�rope. The T. polium is �sed in 
Iranian folk medicine for treating many diseases s�ch as 
abdomonal pain� indigestion� common cold� diabetes� and 
�rogenital diseases. This plant has been reported to have 
hypolipidemic [�]� hypoglycaemic [4]� anti nociceptive 
[5] and anti-inflammatory [6] effects. The few adverse 
effects of T. polium have been reported which indicate 
the relatively safe nat�re of this medicinal herb [7]. The 
Teucrium species are considered as potential so�rce of 
diterpenoidal compo�nds [����]. Anti-cancer chemo-
sensitizer effects of �niq�e diterpenoids were reported 
by several researchers [����4]. In the present st�dy� 
T. polium was examined to eval�ate its chemosensitizer 
effect in vitro. Fo�r conventional chemotherape�tic dr�gs 
�vincristine� vinblastine� doxor�bicin and cisplatin� were 
chosen based on their mechanisms of action and/or their 
chemical str�ct�re. The res�lts showed the potent syner-
gism between methanolic extract of T. Polium �Me-TP� and 
vincristine as well as vinblastine and doxor�bicin against 
a panel of cancero�s cell lines. F�rthermore� the findings 
demonstrated that Me-TP strongly increase the apoptotic 
properties of these dr�gs. 
MATERIALS AND METHODS
Cell lines and cell culture. Skmel-� �Melanoma�� 
Saos-� �osteoblastoma�� SW4�� �colon carcinoma�� 
MCF-7 �breast carcinoma�� KB �oral cavity epidermal 
cell line�� E� �bladder carcinoma� and A4�� �epider-
moid carcinoma� cell lines were p�rchased from Na-
tional Cell Bank of Iran �NCBI�. The cells were grown in 
D�lbecco’s Modified Eagle Medi�m �DMEM� Sigma-
Aldrich� Steinheim� Germany� s�pplemented with ��% 
heat-inactivated fetal calf ser�m �Biochrom� Berlin� 
Germany� and ��� µg/ml streptomycin and ��� �/ml 
penicillin in h�midified 7% CO� atmosphere at �7 °C. 
The skin and l�ng fibroblast cells were obtained from 
a nat�ral aborted h�man fet�s of �� weeks gesta-
tion. Permission to �se h�man embryonic tiss�e was 
granted by the ethical committee of Kerman Medical 
University and with the patient’s consent.
Preparation of Me-TP. The aerial parts of T. Po-
lium were collected d�ring ��ne from the Kohpayeh 
region of Kerman province in the so�th east of Iran. The 
plant materials were dried at room temperat�re and 
were powdered. The dry plant samples were extracted 
with methanol by percolation method. The dry extract 
was obtained after removing the solvent by evaporation 
�nder red�ced press�re and was dissolved in dimethyl 
s�lfoxide ���� mg/ml�.
Cytotoxicity assay. The cytotoxic activities of the 
single agents were assessed in monolayer c�lt�res by 
�sing MTT assay [�5]. In brief� cells were seeded into 
96 well plates �N�nc� Denmark� at �5�� cells/well in 
��� µl of medi�m and allowed to attach for overnight. 
The col�mns � and � as well as the rows A and H of 
plates were filled with sterile distilled water. Then� 5� µl 
of the logarithmically decreasing concentrations of 
vincristine �Gedeon Richter LTD.� B�dapest� H�ngary�� 
vinblastine �Gedeon Richter LTD.� B�dapest� H�ngary� 
or doxor�bicin �Pharmacia & Upjohn� Milan� Italy� were 
added per well and the plates were inc�bated for f�r-
ther three days. The working concentrations of Me-TP 
were ������ µg/ml. The final concentration of DMSO 
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in the highest of applied concentration of Me-TP was 
�.�%. Three wells containing t�mor cells c�lt�red in 
�5� µl of complete medi�m were �sed as controls for 
cell viability. After inc�bation� �� µl of a �.5 mg/ml sol�-
tion of MTT �Sigma-Aldrich� Steinheim� Germany� was 
added to each well and the plates were inc�bated for 
another � h. The c�lt�re medi�m was then replaced 
with ��� µl of DMSO and the absorbance of each well 
was meas�red by �sing a microplate reader at 49� nm. 
Each set of experiments was independently performed 
three times. S�rviving fraction was calc�lated by divid-
ing the absorbance of treated wells by the absorbance 
of control wells × ���. Dose response c�rves were 
generated with respect to s�rviving fraction data and 
the relationship between dose and effect was analyzed 
for the 5�% and ��% inhibitory concentrations �IC5� 
and IC��� by comp�ter fitting the dose-response c�rves 
with linear and nonliner regressions.
Evaluating the effect of Me-TP on the activity of 
the drugs. The cells were seeded into 96 well plates 
as described above. The combined concentrations 
of Me-TP/vincristine� Me-TP/vinblastine and Me-TP/
doxor�bicin as well as the single dr�g concentra-
tions were prepared in � ml sterile t�bes. Then� 5� µl 
of preparations was added per well and plates were 
inc�bated for f�rther three days. Six wells were �sed 
for each concentration. The working concentrations 
of vincristine were �.�� nM for Sk-Mel-� and Saos-� 
cells; �.�6 nM for MCF-7 and �.��� nM for the other 
tested cells. The working concentrations of vinblas-
tine were �.55 nM for Sk-Mel-� and Saos-� cells and 
�.�� nM for MCF-7 cells. The final concentration of 
doxor�bicin was �7.� nM for all the tested cells. These 
concentrations were selected according to the IC5� 
val�es and/or the pretest res�lts. At the end of inc�ba-
tion� MTT assay was performed as described above. 
S�bseq�ently� the combined effects of Me-TP with 
cisplatin �EBEWE Pharma.� Unterach� A�stria� were 
also eval�ated in the same manner with the exception 
that the concentration of Me-TP was kept constant at 
6� µg/ml while cisplatin concentrations were varied 
between �.� to ���� nM. 
In another set of experiments� the combined ef-
fects of Me-TP with vinblastine and vincristine were 
eval�ated on slowly growing h�man embryonic l�ng 
and skin fibroblasts. For this p�rpose� the concentra-
tion of Me-TP was kept constant at 4� µg/ml� while the 
logarithmically decreasing concentrations of the dr�gs 
were applied. The fibroblast cells were seeded into 
96 well plate �� × ��4 cells/well� in DMEM containing 
�.5% FBS. After overnight inc�bation� the combined 
agents were prepared and the remainder proced�re 
was followed as described above.
Colony forming assay. The agarose �Sigma-
Aldrich� Steinheim� Germany� mixt�res were prepared 
by combining of � ml of � × complete DMEM containing 
either vincristine� doxor�bicin� Me-TP alone� or Me-TP 
pl�s these dr�gs with � ml of �.�% melted agarose. 
One milliliter of the mixt�res was then placed onto 
each �5 mm tiss�e c�lt�re plate and left to solidify 
at 4 °C. The selected dr�g concentrations were based 
on maxim�m observed synergistic effects from MTT 
assays and the pretest res�lts. The working dil�tions 
of vincristine were 5 nM for Sk-Mel-� and Saos-� 
cells and �.�5 nM for E� cells� and it was 4� and/or 
�6 nM for doxor�bicin. The final concentrations of 
Me-TP were �� and 6� µg/ml. The cells were then 
trypsinized and res�spended in complete DMEM con-
taining �.�% agarose at a concentration of ���� cells/
ml and one milliliter of s�spension was then added to 
each precoated plate and left to solidify at 4 °C for few 
min�tes. The plates were then placed in 6� mm plates 
containing sterile distilled water and were inc�ba ted at 
�7 °C in h�midified 7% CO� atmosphere for � week. All 
samples were prepared in triplicate. Each experiment 
incl�ded three plates containing dr�g-free medi�m. At 
the end of inc�bation� the n�mber of colonies greater 
than or eq�al to 5� microns in diameter were co�nted 
�nder an inverted microscope with a magnification of 
���-fold. Colony formation rate �CFR� was calc�lated 
by �sing the following form�la: CFR = n�mber of colo-
nies in treated plates / n�mber of colonies in �ntreated 
plates × ���. In addition� the cloning efficiencies �CE� 
of cell lines in the dr�g free-medi�m were calc�lated 
by the following form�la: CE = n�mber of co�nted 
colonies / n�mber of seeded cells × ���. Each set 
of experiments was independently performed three 
times. 
Evaluating the effect of Me-TP on the apoptotic 
activity of the drugs. To verify whether the increase 
of cell death ca�sed by combined treatments was a 
res�lt of apoptosis� the n�clear morphological change 
was assessed by DAPI staining. In brief� Skmel-� and 
Saos-� cells were seeded at a density of � × ��5 cells 
per �5 mm plate and were allowed to adhere for over-
night. The cells were then inc�bated with vincristine 
��.�� nM� or vinblastine ��.55 nM� in the absence or 
presence of Me-TP at �� µg/ml for �6 h. The selected 
concentrations were based on maxim�m observed 
synergistic effects from MTT assay. After inc�bation� 
the medi�m was discarded; the cells were fixed with 
4% paraformaldehyde for �� min� washed with PBS� 
and exposed to DAPI at � µg/ml for 5 min. The prepared 
cells were examined with a fl�orescence microscope. 
Apoptosis was defined when n�clear shrinkage� 
chromatin condensation� or fragmented n�clei were 
observed. Each set of experiments was independently 
performed at least fo�r times. 
Determination of combined effects. The nat�re 
of the interaction between Me-TP and anticancer dr�gs 
in monolayer c�lt�res was analyzed by the combination 
index �CI� method [�6]. A CI val�e < � indicates syner-
gism� and val�es > � indicate antagonism. The nat�re 
of the interaction between Me-TP and anticancer 
dr�gs in soft agarose was analyzed by comparison of 
observed s�rvival val�es with predicted s�rvival val�es 
�PV� calc�lated from the eq�ation: PV = a × b / ���� 
where a and b are s�rvival val�es with single agents. 
The observed val�es < 7�% of the predicted val�es 
were considered synergistic [�7]. 
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RESULTS
The cytotoxic effects of the individual agents 
and the combined treatments on monolayer cell 
growth. Seven h�man cancero�s cell lines were �sed 
in this st�dy which incl�ded five carcinoma cell lines 
�E�� A4��� KB� SW4�� and MCF-7� and two sarcoma 
cell lines �Saos-� and Skmel-��. First� the cytotoxic 
effects of the individ�al agents were determined as 
shown in Fig. � and Table �. Then� the combined ef-
fects of Me-TP with the anticancer dr�gs were eval�-
ated on the panel of cancero�s cell lines. As shown 
by res�lts in Fig. �� a� the combinations of Me-TP 
with vincristine res�lted in a greater growth inhibition 
in all of the cell lines with respect to dr�g alone. For 
instance� in the case of Skmel-�� Saos-� and MCF-7 
cells� vincristine as single agent ��.�� or �.�6 nM� pro-
d�ced � to ��% growth inhibition� b�t its combination 
with Me-TP �4� µg/ml� prod�ced 7� to 77% inhibition. 
Similarly� vinblastine at �.55 or �.�� nM only exhibited 
� to ��% growth inhibition on these cell lines� b�t the 
co-presence of Me-TP �4� µg/ml� res�lted in 6� to 
��% inhibition �Fig. �� b�. Me-TP at 4� µg/ml did not 
have appreciable growth-inhibitory effect �Fig. ��. In 
Saos-� and Skmel-� cells� the combination of Me-TP 
with doxor�bicin had a greater inhibitory effect com-
pared with the individ�al dr�g. In contrast� this com-
bination did not yield any enhanced toxicity over the 
dr�g alone against carcinoma cell lines �Fig. �� c�. In 
addition� Me-TP co�ld not increase the cytotoxic ef-
fects of cisplatin against Saos-� and Skmel-� cell lines 
�data not shown�.
Fig. 1. The growth inhibitory effects of Me-TP on the cancero�s 
cell lines. The cells were treated with the different concentrations 
of Me-TP for three days. Cell growth was determined by MTT assay 
and expressed as percent control. Data represent means ± stan-
dard deviations of three independent experiments
For the p�rpose of comparison� the growth inhibi-
tory effects of vinblastine and vincristine in combina-
tion with Me-TP were determined against non-prolife-
rating l�ng and skin fibroblasts. Fort�nately� Me-TP 
significantly red�ced the toxic effects of vinblastine 
in both skin and l�ng fibroblasts. In contrast� Me-TP 
significantly increased the toxic effects of vincristine 
against l�ng fibroblasts �Fig. ��. 
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Fig. 2. The effects of Me-TP on vincristine-� vinblastine- and 
doxor�bicin-mediated growth inhibition. The cells were treated 
with vincristine �a�� vinblastine �b� and doxor�bicin �c� alone or 
in combination with the different concentrations of Me-TP. The 
cell growth was determined by MTT assay and expressed as 
percent control. Data represent means ± standard deviations 
of three independent experiments
The analysis of combined effects. The com-
bined effects were analyzed for possible synergism 
�sing combination index analysis� at IC�� level. The 
combinations of Me-TP/vincristine showed strong 
Table 1. The growth inhibitory effects of the individual compounds
Cell line
IC50 and IC80 of drugs (nM) and Me-TP (µg/ml)
Vincristine Vinblastine Doxorubicin Me-TP
IC50 IC80 IC50 IC80 IC50 IC80 IC50 IC80
Saos-2 2.8 ± 0.6 17.6 ± 1.6 2.6 ± 2 10.1 ± 1.9 35 ± 11 154 ± 24 109 ± 9.6 189 ± 22.7
Skmel-3 6.9 ± 1.7 12.3 ± 2 1.5 ± 0.5 15.2 ± 4.9 44.7 ± 10 213 ± 71 83 ±7.7 170 ± 12.7
MCF-7 11.6 ± 6.2 159 ± 26 2.8 ± 2.4 91.5 ± 26 ND ND 174 ± 7 277 ± 22
SW480 0.14 ± 0.02 4.9 ± 1.4 > 0.011 < 0.11 14.2 ± 4 165 ± 53 139 ± 23 225 ± 50
KB 0.1 ± 0.01 0.52 ± 0.1 > 0.011 < 0.11 ND ND 174 ± 3 279 ± 33
EJ 0.25 ± 0.1 3.9 ± 0.8 > 0.011 < 0.11 17.2 ± 7 77.4 ± 12 108 ± 14 177 ± 22
A431 0.11 ± 0.02 0.4 ± 0.1 > 0.0011 < 0.011 32.5 ± 2 137 ± 48 93 ± 9 159 ± 2
Note. ND — not determined.
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synergism in the cell growth inhibition in all of the cell 
lines ��.�4 < CIs < �.�5�. In addition� the CI val�es of 
Me-TP/vinblastine combinations showed a remark-
able synergism in the tested cells. Synergism was also 
demonstrated with Me-TP/doxor�bicin combinations 
in Saos-� �CI = �.�� ± �.��� and Skmel-� �CI = �.�� ± 
�.�7� cell lines� b�t not in the carcinoma cell lines 
�CIs > �� �Table ��.
Fig. 3. Effects of Me-TP on the dr�g-mediated growth inhibition 
in the fibroblast cells. The l�ng and Skin fibroblasts were treated 
with vinblastine and vincristine alone or in combination with 
4� µg/ml Me-TP. The cell growth was determined by MTT assay 
and expressed as percent control. Data represent means ± stan-
dard deviations of three independent experiments 
*p < �.�5� **p < �.��� ***p < �.���; St�dent’s t-test.
Table 2. The combination indices for the growth inhibitory effects of 
combined treatments
Cell line Calculated CI for the combined treatmentsVincristine/Me-TP Vinblastine/Me-TP Doxorubicin/Me-TP
Skmel-3 0.29 ± 0.04 0.25 ± 0.05 0.28 ± 0.07
Saos-2 0.26 ± 0.02 0.19 ± 0.05 0.32 ± 0.02
MCF-7 0.19 ± 0.09 0.21 ± 0.02 ND
SW480 0.14 ± 0.04 ND > 1
A431 0.31 ± 0.02 ND > 1
KB 0.35 ± 0.05 ND ND
EJ 0.26 ± 0.06 ND > 1
Note. ND — not determined.
The effects of the combined treatments on 
anchorage independent cell growth. The CEs 
were 46.6 ± 9.�� 5�.9 ± 4 and 55.5 ± 6 for E�� Saos-� 
and Skeml-� cells� respectively. As shown by res�lts 
in table �� the combinations of Me-TP with vincristine 
res�lted in a strong synergistic effect. For example� 
Me-TP �6� µg/ml� only red�ced the CFR of Saos-� and 
Skmel-� cells to 6� ± ��� and 5�.6 ± �%� respectively. 
In addition� vincristine �5.4 nM� as single agent had no 
noticeable effect on the CFR of these cell lines. Under 
the same experimental conditions� the combination of 
Me-TP with vincristine red�ced the CFR of Saos-� and 
Skmel-� cells to �.� ± �.� and � ± �.�%� respectively. 
F�rthermore� doxor�bicin at 4� and �6 nM decreased 
the CFR of Skmel-� cells to �� ± 7 and �9 ± ��%� re-
spectively. The combination of Me-TP �6� µg/ml� with 
doxor�bicin �4� nM� red�ced the CFR of Skmel-� cells 
to �.� ± �.7%. Moreover� �6 nM of doxor�bicin was ef-
ficient to red�ce the CFR of Skmel-� cells to �.6 ± �.5% 
in the presence of �� µg/ml Me-TP. 
Table 3. Effects of Me-TP on the drug-mediated colony formation 
inhibition
Treatments Colony formation rate of cell lines (% of control)Saos-2 Skmel-3 EJ
Vincristine alone 85 ± 11 94 ± 5 49 ± 10
plus 60 µg/ml Me-TP 2.2 ± 1.8 1 ± 1.3 11.3 ± 4
plus 30 µg/ml Me-TP 35 ± 9 8 ± 6 ND
Doxorubicin alone 74 ± 10 82 ± 7 ND
plus 60 µg/ml Me-TP 1.7 ± 2 2.8 ± 2.7 ND
plus 30 µg/ml Me-TP 22 ± 11 1.6 ± 0.5* ND
60 µg/ml Me-TP alone 62 ± 10 53.6 ± 8 69.6 ± 7
30 µg/ml Me-TP alone 84 ± 7 87 ± 10 ND
Notes: *The value was obtained from Me-TP (30 µg/ml) / doxorubicin (86 nM) 
combination. ND — not determined.
The effect of the combined treatments on 
apoptotic cell death. It assessed whether the com-
binations of Me-TP/vincristine and Me-TP/vinblastine 
also ca�se an increased apoptotic death in Skmel-� 
and Saos-� cells. Only �-�% of typical apoptotic cells 
were observed after vincristine ��.�� nM�� vinblas-
tine ��.55 nM� or Me-TP ��� µg/ml� treatments. The 
massive apoptotic cell death �> ��%� was observed 
after the Me-TP/vincristine and Me-TP/vinblastine 
treatments. 
DISCUSSION
The p�rpose of this st�dy was to eval�ate the 
chemosensitizing effectiveness of Me-TP by �sing a 
panel of cancero�s cell lines. Fo�r conventional che-
motherape�tic dr�gs of vincristine� vinblastine� doxo-
r�bicin and cisplatin were eval�ated. These dr�gs were 
chosen based on their mechanisms of action and/or 
their chemical str�ct�re. The combinations of Me-TP 
with vincristine were synergistic in all of the cancero�s 
cell lines. In addition� it was shown that the combina-
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tions of Me-TP with doxor�bicin were only synergistic 
in the sarcoma cell lines. From a clinical point of view� 
the effective concentrations of these dr�gs in the 
combined treatments were as low as that achieved in 
the plasma of treated patients [�����].
Vinca alkaloids s�ch as vincristine and vinblastine 
are well-known cancer therape�tic agents that their 
antit�mor activity is d�e to inhibition of mitotic spindle 
f�nction. Doxor�bicin is a widely �sed anticancer 
agent which its major mode of action appears to be 
as a topoisomerase II poison. These dr�gs ca�se high 
toxicity to the normal tiss�es d�ring the therapy� at 
least in part� d�e to an increase in the level of reactive 
oxygen species [��� ��]. Ideally� a chemosensitizer 
agent sho�ld potentiate and antagonize cytotoxic ef-
fects of another agent in cancero�s cells and normal 
cells� respectively. From the res�lts of the present 
st�dy� it is apparent that Me-TP red�ced the inhibitory 
effects of vincristine and vinblastine toward h�man skin 
and/or l�ng fibroblasts. Consistent with these res�lts� 
several st�dies have reported that nat�ral compo�nds 
which act as free radical scavenging antioxidants 
may be able to red�ce systemic toxicity of anticancer 
dr�gs [��� �4]. In addition� the researchers have pro-
vided evidence that T. Polium has strong antioxidative 
properties in vitro [�5��7]. Therefore� it concl�des that 
Me-TP may be able to antagonize the cytotoxic effects 
of anticancer dr�gs toward normal tiss�es d�e to its 
free radical scavenging properties.
ATP-binding cassette �ABC� transporters� s�ch as 
P-gp/MDR-� are a family of transporter proteins that 
contrib�te to m�ltidr�g resistance via ATP-dependent 
dr�g effl�x p�mps. There are seven s�bfamilies clas-
sified as ABC transporters that are expressed at the 
different levels in both normal and malignant cells [��]. 
The majority of the st�dies have reported the activi-
ty of the chemosensitizing compo�nds against the 
dr�g resistant s�blines �P-gp phenotype� b�t not the 
dr�g sensitive parental cell lines [5� �]. In the present 
st�dy� Me-TP prod�ced the chemosensitizing effects 
toward the dr�g sensitive as well as dr�g resistant 
wild-type cell lines. These res�lts s�ggest that Me-TP 
effectively inhibits a conserved cell�lar phenomenon 
that acts at different levels in all cell lines. In addition� 
the findings showed that the sensitivity of the cells to 
cisplatin� which is a non-s�bstrate for MDR-�� was �n-
changed by the concomitant presence of Me-TP. Since 
vincristine� vinblastine and doxor�bicin are known to 
be the good s�bstrates for Pgp/MDR-�� it concl�des 
that Me-TP may be able to increase the intracell�lar 
dr�g levels by inhibiting Pgp f�nction. However� addi-
tional experiments based on cell�lar �ptake of probe 
compo�nds s�ch as rhodamine-��� �ptake assay are 
req�ired to demonstrate this hypothesis.
Several st�dies have provided evidences that 
cancer chemotherape�tic dr�gs kill s�sceptible 
cancero�s cells by activating apoptotic pathways. 
Conseq�ently� resistance to apoptosis may be a major 
factor for the ineffectiveness of cancer chemothera-
pies [�9� ��]. In this regard� the present findings are 
important where DAPI staining showed that apoptosis 
predominantly contrib�tes to t�mor cell killing ca�sed 
at least by Me-TP/vincristine and Me-TP/vinblastine 
combinations. Therefore� the observed synergism 
between Me-TP and anticancer agents also might be 
d�e to interference with pathways that are involved in 
reg�lation of apoptosis.
CONCLUSION
In concl�sion� the res�lts of present st�dy s�ggest 
that the combinations of Me-TP with anticancer dr�gs 
of vincristine� vinblastine or doxor�bicin may be able 
to increase capability of cancer chemotherapies b�t 
minimize their side effects. However� animal experi-
mentation and clinical trails are req�ired to determine 
if Me-TP has the potential to be an effective and safe 
chemosensitizig agent for cancer therapy.
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МЕТАНОЛЬНый ЭКСТРАКТ TEUCRIUM POLIUM L УСИЛИВАЕТ 
ЦИТОТОКСИЧЕСКОЕ И ПРОАПОПТОТИЧЕСКОЕ ДЕйСТВИЕ 
ВИНКРИСТИНА, ВИНБЛАСТИНА И ДОКСОРУБИЦИНА 
НА ОПУхОЛЕВыЕ КЛЕТКИ
Исследования последних лет показали, что некоторые фитопрепараты могут усиливать эффект химиотерапии. Цель: оценить 
in vitro влияние метанольного экстракта Teucrium Polium (Me-TP) на цитотоксичность и апоптоз, индуцируемые противо-
опухолевыми препаратами винбластином, винкристином и доксорубицином. Методы: в работе использованы клеточные 
линии Skmel-3, Saos-2, SW480, MCF-7, KB, EJ и A431. Цитотоксичность определяли с помощью MTT теста и реакции 
колониеобразования. Характер воздействия препаратов изучали с помощью метода комбинированного индекса (CI). �поп-
тотические клетки выявляли окрашиванием DAPI. Результаты: для комбинаций винкристин/Me-TP, винбластин/Me-TP и 
доксорубицин/Me-TP было выявлено сильное синергичное воздействие на торможение клеточного роста (0,13 < CI < 0,36). 
�налогичные результаты получены при определении способности клеток к колониеобразованию. Более того, комбинации 
винкристин/Me-TP и винбластин/Me-TP вызывали выраженный апоптоз клеток (>  80%) по сравнению с химиопрепаратами 
без Me-TP (0–3%). Показано также, что Me-TP снижал цитотоксическое воздействие (от минимальной до значительной 
степени) винкристина и винбластина на фибробласты человека (p < 0,05 до 0,001). Выводы: Me-TP можно рассматривать 
как возможный эффективный и безопасный химиосенсибилизирующий препарат для химиотерапии. 
Ключевые слова: ингибирование роста, синергический эффект, Teucrium Polium, апоптоз, противоопухолевая терапия.
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